Financial Data and Key Metrics Changes - The company exited the first quarter with approximately $500 million in cash and cash equivalents, earning roughly 5% interest per year [6] - For the full year, the company is budgeting to spend approximately $190 million net of interest income, which includes $45 million for G&A, $50 million for Laporte and R&D activities, and $100 million for SN1 and Baker turbine development [6] Business Line Data and Key Metrics Changes - The focus areas for 2025 include improving project economics for the first utility scale plant by reducing total installed costs and determining a viable commercial pathway to a competitive levelized cost of energy (LCOE) [5][6] - The company is working on quantifying cost savings with greater accuracy and expects meaningful cost reductions with multi-unit deployments, particularly in locations with coastal access [5] Market Data and Key Metrics Changes - The current trading price of the company is near its cash value, indicating that the market assigns little value to its technology compared to other clean power technology companies [7] - The company highlights a significant cost gap between most clean power solutions and natural gas, with recent examples such as Canada announcing new nuclear projects costing significantly more than gas-based power [9] Company Strategy and Development Direction - The company aims to unlock the potential of its unique technology while focusing on cost optimization and commercial success [5][10] - Investment decisions are made with a focus on delivering clean, reliable power from natural gas-based solutions, especially in regions with access to low-cost natural gas [10] Management's Comments on Operating Environment and Future Outlook - Management expresses confidence in the progress being made and the importance of the next few months in driving costs down for projects, thereby improving economics and project fundability [16] - The company believes that the investment in the development of clean gas technology creates the best risk-adjusted return profile for shareholders [17] Other Important Information - The company has no debt and is in a strong financial position to achieve its goals [6] - The new Chief Operating Officer, Mark Horstman, emphasizes the importance of operational excellence and accelerating the path to cost-competitive clean energy [11][12] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.

BrainsWay (BWAY) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Brian Ritchie - Managing DirectorHadar Levy - Chief Executive OfficerIdo Marom - Chief Financial OfficerDestiny Hance - Associate Director of ResearchEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants Steven Lichtman - MD & Senior Analyst - Medical Devices Operator Good day, and welcome to the BrainsWay First Quarter twenty twenty five Earnings Conference Call. All participants wi ...

Perion Network (PERI) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Tal Jacobson - CEO & DirectorElad Tzubery - Chief Financial OfficerJason Helfstein - MD & Head - InternetAndrew Marok - Director Conference Call Participants Eric Martinuzzi - Senior Research AnalystJeff Martin - Director of Research & Senior Research Analyst Operator Hello, everybody, and welcome to the Perion Network Q1 twenty twenty five Earnings Conference Call. Today's conference is being recorded and an archive o ...

Financial Data and Key Metrics Changes - The company ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, an increase from $132 million at the end of 2024, primarily due to $35 million raised from the ATM facility [22][20] - R&D expenses for Q1 2025 were $15.8 million, down from $21.5 million in the same period of 2024, with $9.2 million specifically related to pemidutide development [22][24] - General and administrative expenses rose to $6 million from $5.3 million in Q1 2024, mainly due to increased non-cash stock compensation [23] Business Line Data and Key Metrics Changes - The company is focused on the development of pemidutide, with significant progress in the NASH program, including the upcoming readout of the IMPACT Phase 2b MATCH trial [8][12] - The trial enrolled 212 participants with biopsy-confirmed F2F3 NASH, enhancing the study's power [12] Market Data and Key Metrics Changes - The company is expanding into alcohol use disorder (AUD) and alcohol liver disease (ALD), with plans for Phase II trials in these areas [9][10] - The market research indicates that a drug like pemidutide, which reduces alcohol consumption and liver inflammation, would be well-received by patients and physicians [18] Company Strategy and Development Direction - The company aims to establish pemidutide as a foundational treatment across multiple fibrotic liver diseases, focusing on NASH, AUD, and ALD [10][19] - The strategic partnership with Hercules Capital for a $100 million credit facility is intended to support the ongoing development of pemidutide [9][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the trial's key efficacy and safety objectives for pemidutide, which could become the first therapy to achieve statistical significance on NASH endpoints at 24 weeks [8][13] - The company anticipates 2025 to be a transformative year, with significant milestones expected from the IMPACT trial and the initiation of Phase II trials for AUD and ALD [19][24] Other Important Information - The company is preparing for an end-of-Phase II meeting with the FDA in Q4 2025, which will discuss the potential for accelerated approval in F4 cirrhosis [78][79] - The company has a large safety database for pemidutide, which may allow for more efficient trial designs in Phase III [73] Q&A Session Summary Question: Can you provide commentary on the distribution of F2 and F3 in the Phase 2b population? - Management indicated that the demographics of the final qualifying population are similar to other studies, but precise numbers will be presented later [28][29] Question: What is the ideal population for pemidutide post-IMPACT? - The focus is on treating NASH with obesity, as a significant percentage of NASH patients are obese, which is a key factor in the treatment strategy [30][31] Question: How are you handling study discontinuations? - Management reported satisfaction with the discontinuation rates and stated that data will be available at the time of the readout [36] Question: How important is weight loss in this study? - Weight loss is crucial, as it addresses comorbidities associated with NASH, and the company aims to achieve clinically meaningful weight loss [40][41] Question: What are the expected placebo responses for fibrosis and NASH resolution endpoints? - Management noted that placebo responses have varied historically, but they expect to control the placebo response effectively in their trial [87][88] Question: Will you discuss NASH F4 cirrhosis with the FDA? - The company intends to discuss F4 with the FDA and believes they will be successful in this area [78][79] Question: Can you confirm the cash runway with the Hercules facility? - The facility will provide $15 million upfront, with additional tranches available, potentially extending the cash runway into Q3 2026 [81][82]

Better Home & Finance (BETR) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Tarek Afifi - Corporate Finance ManagerVishal Garg - Founder & CEOKevin Ryan - CFO & PresidentKartik Mehta - Executive MD & Director of ResearchJake Kooyman - Equity Research AssociateEric Hagen - Managing DirectorBose George - Managing Director Conference Call Participants Brendan McCarthy - Equity Research Analyst Operator Hello, and welcome to the Better Home and Finance Holding Company First Quarter twenty t ...

MidCap Financial Investment (MFIC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Elizabeth Besen - Investor Relations ManagerTanner Powell - Chief Executive OfficerTed McNulty - President & CIO - AIMGregory Hunt - CFO & TreasurerKenneth Lee - Vice PresidentHoward Widra - Executive Chairman of the BoardHeli Sheth - Equity Research AssociateMelissa Wedel - Vice President, U.S. Equities ResearchPaul Johnson - Vice President Conference Call Participants Mark Hughes - Analyst Operator morni ...

Financial Data and Key Metrics Changes - The cash position as of March 31 was $115.8 million with no debt [10] - Cash utilized in operating activities during the quarter was $5.9 million [10] - General and administrative expenses decreased to $2.6 million from $2.9 million year-over-year [11] - Research and development expenses increased slightly to $9.9 million from $9.7 million year-over-year [11] - The net loss for the quarter was reported at $11.2 million or $0.13 per share [11] Business Line Data and Key Metrics Changes - The company continues to focus on noninvasive targeted upstream precision compounds, particularly for Alzheimer's disease and schizophrenia [4] - Blacaramazine for Alzheimer's disease showed significant clinical benefits over three years of treatment [5] - Enrollment in the Phase II clinical study of ANAVEX 371 for schizophrenia was successfully completed with 71 participants [6][7] Market Data and Key Metrics Changes - The company is actively engaging with potential partners for the distribution of blacaramazine in Europe [27] - Discussions with CROs are ongoing to establish a sales force for potential drug launch [27] Company Strategy and Development Direction - The company aims to advance precision medicine compounds with a focus on scalable treatment alternatives for Alzheimer's and schizophrenia [13] - The strategy includes preparing for potential drug launches in various international markets, including Europe, Canada, and Australia [32][34] Management's Comments on Operating Environment and Future Outlook - Management expects feedback from the EMA regarding Alzheimer's treatment submission by the end of the year or early next quarter [15] - The focus remains on the safety and biomarker effects of the schizophrenia trial, addressing significant unmet needs in treatment [17][18] Other Important Information - The company has expanded its scientific advisory board with the appointment of experts in Alzheimer's disease [8] - The advantages of oral blacaramazine include timely access to treatment without logistical barriers, benefiting both patients and caregivers [46][49] Q&A Session Summary Question: Timeline for EMA feedback on Alzheimer's treatment - Management expects feedback by the end of the year or early next quarter, with no interim updates provided [15] Question: Key inflection points for 2025 - The focus is on the Phase II study in schizophrenia, particularly on safety and biomarker effects [17] Question: Details on the schizophrenia trial duration - The trial consists of two parts, with Part B lasting 28 days [23] Question: Pre-launch activities for blacaramazine in Europe - The company is in discussions with potential partners and CROs to ensure readiness for distribution [27] Question: Countries that might piggyback on European approval - Other regions include South America, Africa, the Middle East, and parts of Asia [31] Question: Parallel discussions with regulatory bodies - The company plans to initiate discussions with Canadian and Australian authorities in parallel with European feedback [34] Question: Revenue timeline post-approval - Revenue could potentially be realized in the March quarter, depending on logistical factors [41] Question: Drug manufacturing and launch inventory - The drug is manufactured by a major US manufacturer, and the company has a large launch inventory [42]

Intuitive Machines (LUNR) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Stephen Zhang - Head of IRStephen Altemus - Co-Founder, President, CEO & DirectorPete McGrath - Senior VP & Chief Financial OfficerAustin Moeller - Director - Equity ResearchGreg Pendy - Director Conference Call Participants Edison Yu - AnalystAndres Sheppard - AnalystRon Epstein - AnalystGriffin Boss - Equity Research AnalystSuji Desilva - MD & Senior Research AnalystJosh Sullivan - Equity Research Analyst - Indus ...

Humacyte (HUMA) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Tom Johnson - Director - Corporate CommunicationsLaura Niklason - Founder, President, CEO & DirectorDale Sander - CFO, Chief Corporate Development Officer & TreasurerBJ Scheessele - Chief Commercial OfficerJosh Jennings - Managing Director Conference Call Participants Ryan Zimmerman - Managing Director & Medical Technology AnalystKristen Kluska - Managing Director and Biotechnology Equity Research AnalystBruce Jackson - Seni ...

Gladstone Land (LAND) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants David Gladstone - Founder, Chairman, CEO & PresidentMichael Licalsi - General Counsel & SecretaryLewis Parrish - CFO & Assistant TreasurerGaurav Mehta - Managing DirectorRob Stevenson - Managing Director - Head of Real Estate Research Conference Call Participants John Massocca - Senior Research Analyst Operator and welcome to the Gladstone Land Corporation First Quarter Earnings Call. At this time, all participants are ...